Agios Entered into an Exclusive Worldwide License Agreement with Alnylam for siRNA to Treat Polycythemia Vera
Shots:
- Alnylam will receive $17.5M up front for an exclusive global license to the TMPRSS6 siRNA program, ~$130M in development and regulatory milestones along with sales milestones and royalties
- Agios will get rights to develop and commercialize Alnylam’s preclinical siRNA targeting TMPRSS6 for patients with polycythemia vera (PV) & will lead all development, regulatory, and commercial activities and costs related to the program while Alnylam will provide manufacturing support for P-I after which Agios will full responsible for manufacturing
- The agreement combines Agios’ deep scientific expertise and capabilities in rare hematologic diseases with Alnylam’s industry-leading siRNA platform and strong track record of success
Ref: Globenewswire | Image: Agios
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
